That’s a good question.

I firmly believe that our drug is better than Gilead’s, and hopefully that plays out over time. Although, as we know, it is not always the best product that wins out – – there are massive political stakes in this current game.

We have put a tremendous amount of time, energy, and resources into Covid - taking away from other efforts as our resources are limited. Like I said, I think that will bear fruit given the superiority of Leronlimab – – but in the meantime, I think some folks buying / selling the stock are wondering if that was / is the right call - especially given a lack of updates on the other indications. Just my 2 cents.